- Prime Medicine just dropped its first-ever human clinical data — and immediately laid off 25% of its staff. Nothing says “success” like job cuts.
- The company proudly deprioritized the exact program that proved its tech works. Bold strategy: prove it works, then shelve it.
- CEO Keith Gottesdiener is out, replaced by the CFO — because who better to inspire scientific innovation than a finance guy?
- Shares fell nearly 20% on the big day. Apparently the market didn’t get the memo that “proof-of-concept” = “layoffs and panic.”
- Prime claims the restructuring will reduce cash needs “ahead of key inflection points,” aka “we're running out of money.”
- Their new focus: Wilson’s disease, AATD, and a cystic fibrosis collab — because narrowing focus after proving potential is clearly the move.
- The CGD treatment they deprioritized showed actual positive biological results in a human, but they might sell it off. Monetize and forget.
- Jefferies called the data “solid proof-of-concept,” which in biotech apparently translates to “good luck finding your next paycheck.”
- They still have $144 million to burn through, so layoffs might only be the beginning of the “operational excellence” journey.
- Oh, and they’re entering arbitration with Beam over a 2019 deal — because nothing says biotech synergy like legal disputes with your former partner.
There are no replies in this thread yet. Be the first to post a reply below: